Skip to content

Efficacy of botulinum Toxin injection in patients with rotator cuff tendinopathy

Comparing the efficacy of Botulinum Toxin injection and corticosteroid on improving pain, quality of life and shoulder range of motion in patients with rotator cuff tendinopathy

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20240623062220N1
Enrollment
60
Registered
2024-11-24
Start date
2024-11-05
Completion date
Unknown
Last updated
2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Rotator cuff tendinopathy. Condition 2: Rotator cuff tendinopathy. Rotator cuff tear or rupture, not specified as traumatic Rotator cuff tear or rupture, not specified as traumatic

Interventions

Intervention 1: Intervent group:100 units botulinum toxin dysport single dose subacromialion. Intervention 2: Control group: 40 mg of methylprednisolone with lidocaine single dose subacromial.

Sponsors

Artesh University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients who have no history of shoulder surgery, patients who are fully followed up during the intervention, and those who consent to participate in the study. Patients who have received other treatments and have not received an adequate response.

Exclusion criteria

Exclusion criteria: Patients who have a history of shoulder surgery, patients who are not fully followed up during the intervention, those who do not consent to participate in the study, active infection, breastfeeding, pregnancy, myasthenia gravis, aminoglycoside use, allergy to Botulinum toxin or corticosteroid.

Design outcomes

Primary

MeasureTime frame
Intensity of pain. Timepoint: At the beginning of the study, one and three months after the intervention. Method of measurement: Visual Analogue Scale.

Secondary

MeasureTime frame
Quality of life. Timepoint: Before the intervention, one and three months later. Method of measurement: SF36 questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElaheh Asadi amin abadi

Artesh University of Medical Sciences

E.asadi@ajaums.ac.ir+98 913 412 2139

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026